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To The Editor,
I sincerely thank the reader for going through my article [1]
and raising his doubts. In fact, this review was written basically
for general pediatricians about the practical management of 
acute immune thrombocytopenic purpura in children keeping in
view the recommendations of American Society of Hematology
[ASH] [2]. So the purpose of writing this paper was not to go 
into the details of the definition and disease process and, also,
not to discuss investigations which were not cost effective. The
recommendations of ASH [2] resembled to those of British 
Committee for Standards in Haematology {BCHS} [3] with a few
differences. 
I used the definition according to ASH [2]. So acute immune
thrombocytopenic purpura (ITP) and acute idiopathic 
thrombocytopenic purpura are interchangeable terms 
[2]. The ASH defined  ITP as [2] isolated thrombocytopenia with
no clinically apparent associated conditions or other 
causes of thrombocytopenia (e.g., HIV infection, systemic lupus
erythematosus, lymphoproliferative disorders, myelodysplasia,
agammaglobulinemia or hypogammaglobulinemia, drug-indu-
ced thrombocytopenia, alloimmune thrombocytopenia, 
congenital hereditary nonimmune thrombocytopenia) . Patients
with isolated abnormalities on serologic tests (e.g., antinuclear or
antiphospholipid antibodies) but without a clinically evident 
disorder such as systemic lupus erythematosus were not 
excluded because positive serologic tests are frequently 
encountered in patients with typical ITP [2], so the mere 
presence of isolated positive coombs test or other positive 
serologic tests has no significance in the diagnosis and that is
the reason I did not mention such investigations.
AS far as the antiplatelet antibodies are concerned It is true
that a positive antigen-specific assay provides confirmatory 
evidence for the diagnosis in patients suspected of having 
immune thrombocytopenia while a negative test does not rule it
out [4] platelet bound autoantibodies can be detected
With a sensitivity of 49–66% and a specificity of 78–93% when
patients suspected of having ITP are compared with healthy 
individuals or patients with nonimmune thrombocytopenia [5]
The frequency of positive assays and the degree of positivity
increases with disease severity [6] and the presence or absence
of autoantibodies has prognostic significance [7]. Interlaboratory
standardization of platelet antibody assays, however, has been
difficult to achieve [8].
Measurement of antibodies in plasma or serum has been
less reliable. There have been no prospective studies using 
platelet antibody determinations to make or to exclude the 
diagnosis of ITP and act accordingly. Hence, the diagnosis of
ITP does not rest on the results of platelet antibody testing, 
although a positive direct assay may provide useful confirmatory
evidence, particularly in patients who have immune 
thrombocytopenia in the setting of another disease [4]. The 
detection of antiplatelet antibodies does not discriminate 
between acute, chronic, and secondary causes of 
immune-mediated platelet destruction. For these reasons, 
antiplatelet antibody testing is not currently recommended for
the initial diagnosis of ITP [9].
ASH [2] recommends IVIG as first line of drug if any is to be
used while BCSH [3] reserves it for emergency treatment of 
patients who do not remit or respond to steroids and who have
active bleeding.
Tarantino MD et al. 2007 [10] updated the management 
guidelines published by ASH and BSCH and found very little
change in overall management of acute ITP.
It is recommended that the bone marrow be examined 
before steroid therapy is given [2,3] A brief course of high-dose
prednisone is an inexpensive about more than three times 
cheaper than IV IG acute ITP (11) but the only drawback is the
procedure of bone marrow biopsy for marrow examination
which is painful and is more acceptable when performed under
general anaesthesia [3] But Geddis AE [9] et al. 2007 concluded
in their study that bone marrow examination is not needed prior
to initiation of therapy in children who present with isolated
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clinical or hematologic features that are atypical of ITP. So I 
agree with reader’s opinion about that methylprednisolone is
better choice if cost is concerned. 
As far the platelet transfusions in acute ITP is concerned, the
only indication is life threatening bleeding (e.g. ICH which is 
luckily very rare) but in combination with iv methylprednisolone
and or IV IG [2,3]. Plasmapheresis is not indicated in life 
threatening conditions [1,2] and not available in most centers.
There is no doubt that the reader not only focused platelet
count but also antiplatelet antibody response in his study [12]
but my sentence in the article [1] “In brief, to date, virtually all of
the randomized clinical trials conducted in children with ITP 
have focused on platelet counts as the sole outcome measure”
was just to put emphasize that the response outcome 
measured was not the clinical improvement but it was just 
improvement in platelet count. But even the said study [12] did
not measure the clinical outcome.
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